Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.81 +0.99 (+5.56%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

22 23 Next >

Sarepta Downgraded As FDA Decision Date Approaches, Shares Up 50% Over Last Six Months ↗

May 28, 2024

RBC Capital Markets downgrades Sarepta Therapeutics following increased FDA label expansion expectations for Elevidys and recent stock surge.

Via Benzinga

Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 28, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 24, 2024

Via Benzinga

12 Analysts Have This To Say About Sarepta Therapeutics ↗

May 20, 2024

Via Benzinga

What Analysts Are Saying About Sarepta Therapeutics Stock ↗

May 02, 2024

Via Benzinga

Sarepta Therapeutics: Q4 Earnings Insights ↗

February 28, 2024

Via Benzinga

The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now ↗

May 23, 2024

With interest cuts on the horizon, it's a prime time to consider these high-risk-high-reward biotech stocks to buy.

Via InvestorPlace

Jim Cramer: This Industrial Stock Is Doing 'Very Well'; Here's His Take On Palantir ↗

May 22, 2024

Jim Cramer likes Enbridge Inc. (NYSE: ENB), says Lazard, Inc. (NYSE: LAZ) is a good buy, and Advanced Drainage Systems, Inc. (NYSE: WMS) is an incredible infrastructure play. He also mentions Jacobs...

Via Benzinga

Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again ↗

May 20, 2024

Dyne Therapeutics is looking to take on Sarepta Therapeutics in DMD.

Via Investor's Business Daily

3 Biotech Stocks With the Potential to Make You an Overnight Millionaire ↗

May 04, 2024

Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments.

Via InvestorPlace

Apple, Kellanova And 3 Stocks To Watch Heading Into Thursday ↗

May 02, 2024

Via Benzinga

A Preview Of Sarepta Therapeutics's Earnings ↗

February 27, 2024

Via Benzinga

SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

May 01, 2024

SRPT stock results show that Sarepta Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript ↗

May 01, 2024

SRPT earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

1 Top Growth Stock to Buy and Hold for 10 Years ↗

May 01, 2024

This company's lineup might look very different in a decade, but the end result will be the same for investors.

Via The Motley Fool

Sarepta Therapeutics Stock Shows Improved Technical Strength ↗

April 29, 2024

The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73.

Via Investor's Business Daily

Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst ↗

April 08, 2024

Sarepta stock has taken a beating this year, and it might not be over with the first-quarter report looming.

Via Investor's Business Daily

2 Biotech Stocks to Buy Hand Over Fist in April ↗

April 06, 2024

These drugmakers have made important moves over the past year.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

April 04, 2024

Via Benzinga

How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback ↗

March 28, 2024

The company could follow Sarepta Therapeutics with a gene therapy for Duchenne muscular dystrophy.

Via Investor's Business Daily

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? ↗

March 13, 2024

The threat is still emerging, but it could be significant.

Via The Motley Fool

This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO ↗

March 08, 2024

REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients.

Via Benzinga

Got $1,000? Buy These Hot Growth Stocks Before They Take Off. ↗

March 08, 2024

These stocks haven't been able to get much traction lately, even though they clearly deserve to now.

Via The Motley Fool

Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst ↗

March 04, 2024

The upcoming regulatory decision on its latest drug could be big.

Via The Motley Fool

Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript ↗

February 29, 2024

SRPT earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Is It Too Late to Buy Sarepta Therapeutics Stock? ↗

February 28, 2024

The company's hyperfocus on its core area could continue to be highly lucrative.

Via The Motley Fool

Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices ↗

February 26, 2024

Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

February 19, 2024

Via Benzinga

Earnings Scheduled For February 28, 2024 ↗

February 28, 2024

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

February 19, 2024

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

Headline News about Sarepta Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today